Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance

Wiener Klinische Wochenschrift

Volumn 108, Issue 19, 1996, Pages 607-610

  Melichart, Madeleine ^a   Kyrle, P A ^a   Eichinger, Sabine ^a   Rintelen, Claudia ^a   Mannhalter, Christine ^a   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

APC resistance; factor V Leiden; thrombophilia; venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; SYMPTOM; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; PULMONARY EMBOLISM; RECEPTORS, CELL SURFACE; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0029860061     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67
2. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP (1995) Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74: 449-453
3. Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90: 1004-1008
4. Dahlbäck B, Hildebrand B (1994) Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 91: 1396-1400
5. Griffin JH, Evatt B, Wideman G, Fernández JA (1993) Anticoagulant protein C pathway defective in majority of thrombophilic patients Blood 82: 1989-1993
6. Halbmayer WM, Haushofer A, Schön R, Fischer M (1994) The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 5: 51-57
7. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 342: 1503-1506
8. Leroy-Matheron C, Levent M, Pignon JM, Mendoça C, Gouault-Heilmann M (1996) The 1691 G-A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 75: 4-10
9. Mannhalter C, Huber H, Löffler H, Faber V (1994) Molekularbiologie in der medizinischen Diagnostik. In: Methoden der diagnostischen Hämatologie. Springer, Berlin Heidelberg New York Tokyo, pp 215-261
10. Pabinger I, Brücker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K (1992) Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibrinol 3: 547-553
11. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennenkens CH (1995) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92: 2800-2802
12. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter CH (1996) Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 75: 229-232
13. Rintelen C, Mannhalter CH, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I (1996) Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at young age in females homozygous for factor V Leiden. Br J Haematol 93: 487-490
14. Rosen S, Johansson K, Lindberg K, Dahlbäck B (1994) Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 72: 255-260
15. Rosendaal FR (1996) Oral contraceptives and screening for factor V Leiden. Thromb Haemost 75: 524-525
16. Szucs T, Osterkorn D, Schramm W (1996) Gesundheitsökonomische Evaluation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern. Medizinische Klinik 91: 317-319
17. Svensson PJ, Dahlbäck B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517-522
18. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 344: 1453-1457